Duration of antiplatelet therapy after DES implantation: can we trust non-inferiority open-label trials?
FACT (French Alliance for Cardiovascular Trials), an F-CRIN Network, DHU FIRE, Paris, France.|Université Paris-Diderot, Paris, France.|INSERM U1148, Paris, France.|Cardiology, Hôpital Bichat, AP-HP, Paris, France.|Imperial College, NHLI, Royal Brompton Hospital, London, UK.
Philippe Gabriel
PG
Steg
FACT (French Alliance for Cardiovascular Trials), an F-CRIN Network, DHU FIRE, Paris, France.|INSERM U1148, Paris, France.|Department of Clinical Pharmacology, Unité de Recherche Clinique de l'Est Parisien (URC-EST), AP-HP, Paris, France.|Université Pierre et Marie Curie, Paris, France.
Tabassome
T
Simon
D004359:Drug Therapy, Combination; D054855:Drug-Eluting Stents; D006801:Humans; D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine
D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine